EXELIXIS, INC. (EXEL) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 32 days, typically, give or take 6 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Oct 29, 2026after close 27 8-K
Q2 FY2026Wed, Aug 5, 2026after close 33 8-K
Q1 FY2026Tue, May 5, 2026after close 32 8-K
Q4 FY2025Tue, Feb 10, 2026after close 39 8-K
Q3 FY2025Tue, Nov 4, 2025after close 32 8-K
Q2 FY2025Mon, Jul 28, 2025after close 24 8-K
Q1 FY2025Tue, May 13, 2025after close 39 8-K
Q4 FY2024Tue, Feb 11, 2025after close 39 8-K

What they guided beta

Q3 FY2026 "The decrease in collaboration revenues was primarily related to lower milestone-related revenues recognized in the quarter and lower development cost reimbursements earned, partially offset by - more - Exelixis Third Quarter 2026 Financial Results Page 2 of 9 October 29, 2026 higher royalty revenues for the sales of cabozantinib outside the U.S. generated by Exelixis’ collaboration partner Ipsen Pharma SAS (Ipsen)." exhibit
Q3 FY2026 "GAAP net income per share for the quarter ended September 30, 2026 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended September 30, 2026, as compared to the comparable period in 2025, as a result of the stock repurchase programs." exhibit
Q3 FY2026 "Reconciliations between GAAP and non-GAAP results are presented in the tables of this release. - more - Exelixis Third Quarter 2026 Financial Results Page 3 of 9 October 29, 2026 2026 Financial Guidance Exelixis is providing the following updated financial guidance for fiscal year 2026." exhibit
Q3 FY2026 "Current Guidance (provided on October 29, 2026) Previous Guidance (provided on August 5, 2026) Total revenues $2.500 billion - $2.550 billion $2.500 billion - $2.550 billion Net product revenues $2.300 billion - $2.350 billion (1) $2.300 billion - $2.350 billion (1) Cost of goods sold, % of net product revenues ~4% 3.5% - 4.5% Research and development expenses $825 million - $875 million (2) $825 million - $875 million (2) Selling, general and administrative expenses $575 million - $625 million (3) $575 million - $625 million (3) Effective tax rate 16% - 18% 21% - 23% ____________________ (1)" exhibit
Q3 FY2026 "Zanzalintinib GU Highlights Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027." exhibit
Q2 FY2026 "GAAP net income per share for the quarter ended June 30, 2026 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended June 30, 2026, as compared to the comparable period in 2025, as a result of the stock repurchase programs." exhibit
Q2 FY2026 "Reconciliations between GAAP and non-GAAP results are presented in the tables of this release. - more - Exelixis Second Quarter 2026 Financial Results Page 3 of 9 August 5, 2026 2026 Financial Guidance Exelixis is providing the following updated financial guidance for fiscal year 2026." exhibit
Q2 FY2026 "Current Guidance (provided on August 5, 2026) Previous Guidance (provided on January 11, 2026) Total revenues $2.500 billion - $2.550 billion $2.525 billion - $2.625 billion Net product revenues $2.300 billion - $2.350 billion (1) $2.325 billion - $2.425 billion (1) Cost of goods sold, % of net product revenues 3.5% - 4.5% 3.5% - 4.5% Research and development expenses $825 million - $875 million (2) $875 million - $925 million (2) Selling, general and administrative expenses $575 million - $625 million (3) $575 million - $625 million (3) Effective tax rate 21% - 23% 21% - 23% ________________" exhibit
Q2 FY2026 "Exelixis remains on track to initiate the planned phase 3 STELLAR-316 pivotal trial of zanzalintinib in mid-2026." exhibit
Q2 FY2026 "Zanzalintinib GU Highlights Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/EXEL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/EXEL

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

EXEL earnings date badge

HTML

<a href="https://veritasdata.dev/company/EXEL/"><img src="https://veritasdata.dev/embed/EXEL.svg" alt="EXEL earnings date" width="240" height="56"></a>

Markdown

[![EXEL earnings date](https://veritasdata.dev/embed/EXEL.svg)](https://veritasdata.dev/company/EXEL/)

Script

<script async src="https://veritasdata.dev/embed/EXEL.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/EXEL"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.